Metsera Competitors

Delisted . USA . 
Stock . Metsera Common Stock
MTSRDelisted Stock   70.50  0.00  0.00%   
Metsera Common Stock competes with Nuvalent, Axsome Therapeutics, Crispr Therapeutics, Cytokinetics, and Vaxcyte; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Metsera Common competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Metsera Common to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Metsera Common vs Arcellx Correlation

Excellent diversification

The correlation between Metsera Common Stock and ACLX is -0.65 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Metsera Common Stock and ACLX in the same portfolio, assuming nothing else is changed.

Moving together with Metsera Stock

  0.72GPOVF Grupo Carso SABPairCorr

Moving against Metsera Stock

  0.85ORGN Origin MaterialsPairCorr
  0.81HPQ HP IncPairCorr
  0.36T ATT Inc Aggressive PushPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Metsera Common's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
64.6670.2275.78
Details
Intrinsic
Valuation
LowRealHigh
48.9454.5077.55
Details
Naive
Forecast
LowNextHigh
65.4471.0176.57
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
29.7354.1878.62
Details

Metsera Common Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Metsera Common and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Metsera and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Metsera Common Stock does not affect the price movement of the other competitor.

High positive correlations

PCVX
+ 0.69
AXSM
ARWR
+ 0.64
AXSM
PCVX
+ 0.55
NUVL
ARWR
+ 0.55
ABVX
PCVX
+ 0.52
CYTK
ABVX
+ 0.5
NUVL
  

High negative correlations

ACLX
- 0.92
ARWR
ACLX
- 0.6
AXSM
ACLX
- 0.58
ABVX
PCVX
- 0.39
CRSP
ACLX
- 0.39
NUVL
ACLX
- 0.35
RYTM

Risk-Adjusted Indicators

There is a big difference between Metsera Stock performing well and Metsera Common Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Metsera Common's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Metsera Common Competitive Analysis

The better you understand Metsera Common competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Metsera Common's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Metsera Common's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MTSR NUVL AXSM CRSP CYTK PCVX RYTM ABVX ARWR ACLX
 0.00 
 70.50 
Metsera
 3.90 
 100.90 
Nuvalent
 2.53 
 180.84 
Axsome
 8.55 
 45.88 
Crispr
 5.16 
 60.24 
Cytokinetics
 2.48 
 53.91 
Vaxcyte
 3.80 
 103.87 
Rhythm
 2.52 
 110.71 
Abivax
 5.02 
 64.64 
Arrowhead
 3.52 
 66.94 
Arcellx
Market Volatility
(90 Days Market Risk)
Not too volatile
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Weakest
Mild
Good
Weakest
Soft
Good
Soft
Soft
Solid
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Low
Low
Low
Small
Low
Small
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Hold
Hold
Cautious Hold
Strong Hold
Sell
Strong Sell
Strong Hold
Strong Sell
Current Ratio
N/A
25.79
2.44
17.57
9.01
11.94
5.59
N/A
3.37
10.16
Net Asset
450.99 M
1.14 B
568.5 M
2.24 B
1.4 B
3.51 B
392.27 M
205.23 M
1.45 B
711.33 M
Profit Margin
N/A
N/A
-0.41
N/A
N/A
N/A
-1.1
N/A
-0.002
N/A
EBITDA
(218.23 M)
(280.37 M)
(272.6 M)
(447.31 M)
(493.48 M)
(448.08 M)
(238.09 M)
(171.88 M)
164.82 M
(99.06 M)
Current Valuation
6.98 B
7.21 B
9.26 B
3.19 B
8.2 B
5.89 B
7.01 B
8.06 B
9.67 B
3.61 B
Price To Book
22.03
9.84
127.1
2.59
60.31
2.77
48.56
14.74
21.66
9.11
Operating Margin
N/A
N/A
-0.19
-148.55
-86.13
N/A
-1.03
-44.41
0.17
-12.48
Retained Earnings
(257.15 M)
(547.05 M)
(1.12 B)
(1.37 B)
(2.7 B)
(1.39 B)
(1.16 B)
(438.88 M)
(1.63 B)
(496.83 M)
Current Asset
N/A
N/A
34.76 M
232 M
113.11 M
N/A
N/A
N/A
90.5 M
N/A
Beta
N/A
1.32
0.4
1.75
0.55
1.34
2.04
-0.11
1.22
0.36
Number Of Employees
125
218
816
393
498
414
283
67
711
163
Shares Outstanding
105.38 M
67.27 M
50.41 M
95.3 M
122.26 M
130.91 M
66.74 M
77.83 M
140.01 M
57.82 M
Cash Flow From Operations
(99.79 M)
(185.06 M)
(128.41 M)
(142.77 M)
(395.89 M)
(452.63 M)
(113.88 M)
(154.07 M)
179.55 M
(83.47 M)
Total Debt
9.8 M
71.96 M
192.96 M
223.69 M
788.68 M
71.11 M
3.94 M
97.36 M
733.68 M
54.08 M
Return On Equity
-1.35
-0.39
-2.75
-0.25
-5.72
-0.21
-0.86
-5.0
0.0867
-0.47
Return On Asset
-0.39
-0.23
-0.2
-0.13
-0.25
-0.15
-0.27
-0.58
0.0487
-0.21
Number Of Shares Shorted
4.77 M
5.75 M
2.71 M
21.74 M
13.39 M
12.1 M
6.29 M
3.08 M
10.79 M
9.12 M
Book Value Per Share
3.21
11.7
1.47
20.41
-4.26
22.25
2.23
-0.76
3.43
7.63
Current Liabilities
N/A
5.46 M
6.74 M
78 M
31.65 M
N/A
N/A
N/A
25.64 M
N/A
Total Asset
450.99 M
1.14 B
568.5 M
2.24 B
1.4 B
3.51 B
392.27 M
205.23 M
1.45 B
711.33 M
Short Ratio
2.52
10.5
3.53
13.1
6.08
10.63
8.42
1.56
4.02
9.98
Target Price
57.0
141.71
215.44
84.39
89.94
102.11
141.57
123.78
81.92
112.35
Debt To Equity
N/A
2.81
6.2
0.12
2.93
0.057
0.011
N/A
0.17
0.094
Shares Owned By Institutions
90.23
97.3
77.37
77.8
99.27
99.53
99.36
49.0
82.78
87.09
Market Capitalization
7.43 B
7.79 B
9.44 B
4.96 B
7.91 B
7.3 B
7.23 B
8.19 B
9.53 B
4.01 B
Price To Earning
N/A
-0.06
-3.34
17.33
-37.76
N/A
N/A
N/A
482.39
N/A
Price To Earnings To Growth
N/A
N/A
N/A
-0.21
-0.42
-11.32
0.75
N/A
-1.32
-0.07
Price To Sales
N/A
N/A
16.83
129.26
90.75
N/A
41.45
1673.75
11.49
111.75
Net Income
(209.13 M)
(260.76 M)
(287.22 M)
(366.25 M)
(589.53 M)
(463.93 M)
(260.6 M)
(176.24 M)
30.11 M
(107.35 M)
Earnings Per Share
-2.99
-5.33
-4.67
-5.54
-6.3
-4.85
-3.1
-3.58
-0.01
-3.93
Shares Owned By Insiders
13.04
2.71
15.69
1.58
0.73
0.47
0.64
N/A
3.8
12.91
Revenue
N/A
N/A
385.69 M
35 M
18.47 M
N/A
130.13 M
10.79 M
829.45 M
107.94 M
Working Capital
291.83 M
1.08 B
254.96 M
1.85 B
928.27 M
1.65 B
258.68 M
77.84 M
755.15 M
473.9 M
Cash And Equivalents
N/A
256.96 M
73.39 M
2.07 B
586.03 M
354.5 M
235.6 M
N/A
416.5 M
306.99 M
Cash Per Share
N/A
5.31
1.82
26.48
6.22
5.98
4.64
N/A
3.93
7.01
Gross Profit
N/A
N/A
515.6 M
(430.67 M)
(318.05 M)
(75 M)
155.86 M
6.02 M
829.45 M
(132.27 M)
Day Typical Price
70.5
103.25
183.1
47.01
61.6
54.54
105.99
111.67
66.03
68.22
Accumulation Distribution
N/A
43485.76
39850.75
216997.0
130224.0
113996.0
44744.06
33025.74
260005.0
71694.1
Daily Balance Of Power
0.0
(0.46)
(0.56)
(1.05)
(0.74)
(0.40)
(0.53)
(0.47)
(0.61)
(0.51)
Period Momentum Indicator
N/A
(4.09)
(4.70)
(4.29)
(3.28)
(1.37)
(4.10)
(2.86)
(3.42)
(2.44)
Rate Of Daily Change
1.0
0.96
0.97
0.91
0.95
0.98
0.96
0.97
0.95
0.96
Day Median Price
70.5
104.43
184.24
47.58
62.28
54.85
107.05
112.15
66.72
68.85
Price Action Indicator
N/A
(5.57)
(5.74)
(3.84)
(3.68)
(1.63)
(5.23)
(2.87)
(3.80)
(3.13)
Coefficient Of Variation
558.96
2097.46
604.76
(1,490)
4081.77
860.69
0
1998.13
604.38
(1,141)
Mean Deviation
4.01
2.22
1.83
2.65
2.12
2.48
2.47
3.14
3.49
2.2
Jensen Alpha
1.75
0.146
0.5695
(0.34)
0.0123
0.2982
(0.07)
0.2345
0.7137
(0.29)
Total Risk Alpha
0.9266
(0.09)
0.2959
(0.51)
(0.14)
0.1241
(0.25)
(0.12)
0.4563
(0.55)
Sortino Ratio
0.459
0.0297
0.3
N/A
(0.0007)
0.116
N/A
0.0438
0.2073
N/A
Downside Variance
11.18
8.07
2.67
N/A
5.28
6.95
N/A
13.52
14.15
N/A
Standard Deviation
8.94
3.12
3.35
3.53
2.57
3.19
3.29
4.51
5.1
3.35
Kurtosis
30.45
3.33
29.62
1.42
(0.28)
0.3128
1.99
5.58
5.11
8.43
Potential Upside
14.25
4.1
4.2
5.31
4.25
6.71
4.76
6.94
10.85
4.75
Treynor Ratio
(0.55)
(1.07)
(1.18)
(0.15)
0.071
0.316
(0.01)
(0.62)
0.3764
1.06
Maximum Drawdown
75.6
17.72
26.78
19.81
10.86
15.14
18.69
29.38
32.02
22.18
Variance
79.87
9.75
11.24
12.47
6.61
10.16
10.84
20.33
26.05
11.2
Market Risk Adjusted Performance
(0.54)
(1.06)
(1.17)
(0.14)
0.081
0.326
3.0E-4
(0.61)
0.3864
1.07
Risk Adjusted Performance
0.1408
0.0427
0.1294
(0.04)
0.0252
0.0932
0.0078
0.0452
0.1303
(0.06)
Skewness
4.87
1.03
4.56
0.3448
0.312
0.2762
0.5059
1.42
1.57
(1.65)
Semi Deviation
2.4
2.77
1.27
N/A
2.25
2.49
N/A
3.49
2.97
N/A
Information Ratio
0.1717
0.027
0.1461
(0.09)
(0.0006)
0.0959
(0.02)
0.0357
0.1528
(0.11)
Value At Risk
(4.09)
(4.96)
(2.36)
(5.47)
(3.67)
(3.46)
(5.14)
(6.09)
(5.77)
(4.57)
Expected Short fall
(5.30)
(2.24)
(2.33)
N/A
(2.47)
(3.09)
N/A
(3.56)
(3.87)
N/A
Downside Deviation
3.34
2.84
1.63
N/A
2.3
2.64
N/A
3.68
3.76
N/A
Semi Variance
5.75
7.65
1.62
N/A
5.07
6.18
N/A
12.17
8.84
N/A

Metsera Common Competition Performance Charts

Five steps to successful analysis of Metsera Common Competition

Metsera Common's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Metsera Common Stock in relation to its competition. Metsera Common's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Metsera Common in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Metsera Common's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Metsera Common Stock, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Metsera Common position

In addition to having Metsera Common in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large Value Funds Thematic Idea Now

Large Value Funds
Large Value Funds Theme
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Value Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Other Consideration for investing in Metsera Stock

If you are still planning to invest in Metsera Common Stock check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Metsera Common's history and understand the potential risks before investing.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY